Statement of Changes in Beneficial Ownership (4)
April 11 2016 - 4:24PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Proniuk Stefan
|
2. Issuer Name
and
Ticker or Trading Symbol
Arno Therapeutics, Inc
[
ARNI
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Development Officer
|
(Last)
(First)
(Middle)
200 ROUTE 31 NORTH, SUITE 104
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/7/2016
|
(Street)
FLEMINGTON, NJ 08822
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
|
|
|
|
|
|
|
10047
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy)
|
$2.40
|
|
|
|
|
|
|
(1)
|
6/20/2021
|
Common Stock
|
17187
|
|
17187
|
D
|
|
Stock Option (right to buy)
|
$2.40
|
|
|
|
|
|
|
(1)
|
6/20/2021
|
Common Stock
|
7191
|
|
7191
|
D
|
|
Stock Option (right to buy)
|
$2.40
|
|
|
|
|
|
|
(1)
|
9/19/2021
|
Common Stock
|
10000
|
|
10000
|
D
|
|
Stock Option (right to buy)
|
$2.40
|
|
|
|
|
|
|
(1)
|
1/14/2023
|
Common Stock
|
6875
|
|
6875
|
D
|
|
Stock Option (right to buy)
|
$2.40
|
|
|
|
|
|
|
(1)
|
1/14/2023
|
Common Stock
|
2291
|
|
2291
|
D
|
|
Stock Option (right to buy)
|
$2.40
|
|
|
|
|
|
|
(2)
|
11/4/2023
|
Common Stock
|
45701
|
|
45701
|
D
|
|
Stock Option (right to buy)
|
$2.90
|
|
|
|
|
|
|
(3)
|
1/24/2024
|
Common Stock
|
171877
|
|
171877
|
D
|
|
Stock Option (right to buy)
|
$.37
|
4/7/2016
|
|
A
|
|
554685
|
|
(4)
|
4/7/2026
|
Common Stock
|
554685
|
$0
|
554685
|
D
|
|
2012 Series A Warrants (right to buy)
|
$1.36
(5)
|
|
|
|
|
|
|
11/26/2012
|
11/26/2017
|
Common Stock
|
24508
(5)
|
|
24508
(5)
|
D
|
|
Explanation of Responses:
|
(
1)
|
Currently exercisable.
|
(
2)
|
Vests in equal 36-monthly installments commencing 12/4/13.
|
(
3)
|
Vests 25% on first anniversary date and thereafter will vest in 24 equal monthly installments.
|
(
4)
|
Vests one-third on the first anniversary of grant and thereafter in 24 equal monthly installments.
|
(
5)
|
As a result of the Issuer's 1/12/16 private placement of common stock at $0.35/share, the exercise price and number of shares subject to the 2012 Series A Warrants were automatically adjusted to the exercise price and shares reflected, pursuant to anti-dilution adjustment provisions.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Proniuk Stefan
200 ROUTE 31 NORTH
SUITE 104
FLEMINGTON, NJ 08822
|
|
|
Chief Development Officer
|
|
Signatures
|
/s/ Christopher J. Melsha as Attorney-in-Fact for Stefan Proniuk, Ph.D. pursuant to Power of Attorney previously filed.
|
|
4/11/2016
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024